(4-(4-Amino-6-hydroxy-7-methoxyquinazolin-2-yl)piperazin-1-yl)(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanone

Catalog No. :
ACZLSB439
CAS No. :
102932-26-3
Molecular Formula :
C22H23N5O5
Molecular Weight :
437.46

IUPAC Name:(4-(4-amino-6-hydroxy-7-methoxyquinazolin-2-yl)piperazin-1-yl)(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanone

(4-(4-Amino-6-hydroxy-7-methoxyquinazolin-2-yl)piperazin-1-yl)(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanone structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(4-(4-Amino-6-hydroxy-7-methoxyquinazolin-2-yl)piperazin-1-yl)(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanone
IUPAC Name(4-(4-amino-6-hydroxy-7-methoxyquinazolin-2-yl)piperazin-1-yl)(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanone
Molecular FormulaC22H23N5O5
Molecular Weight437.46
SMILESO=C(C1COC2=CC=CC=C2O1)N3CCN(CC3)C4=NC(N)=C5C=C(C(OC)=CC5=N4)O
InChI KeyDSVHRYIETHRCFI-UHFFFAOYSA-N
Synonym1-(4-Amino-6-hydroxy-7-methoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl-piperazine;6-HYDROXY DOXAZOSIN;Methanone, [4-(4-amino-6-hydroxy-7-methoxy-2-quinazolinyl)-1-piperazinyl](2,3-dihydro-1,4-benzodioxin-2-yl)-;Doxazosin Impurity 12;Gentisuric Acid Impurity 1;Doxazosin Impurity 6 HCl
CAS No.102932-26-3

Synthetic Route by SureRoute

1. ACZLSB439 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACVSCI231 route compound structure diagram
    ACVSCI2313663-80-7 In Stock
  4. Then
  5. ACZLSB439 route product structure diagram
    ACZLSB439102932-26-3
Inquiry

2. ACZLSB439 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACZLSB439 route product structure diagram
    ACZLSB439102932-26-3
Inquiry

Comments (0)